Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/23504
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorALVARADO-MORA, Monica Viviana-
dc.contributor.authorFERNANDEZ, Maria Fernanda Gutierrez-
dc.contributor.authorGOMES-GOUVEA, Michele Soares-
dc.contributor.authorAZEVEDO NETO, Raymundo Soares de-
dc.contributor.authorCARRILHO, Flair Jose-
dc.contributor.authorPINHO, Joao Renato Rebello-
dc.date.accessioned2017-11-27T16:35:10Z-
dc.date.available2017-11-27T16:35:10Z-
dc.date.issued2011-
dc.identifier.citationPLOS ONE, v.6, n.4, article ID e18888, 6p, 2011-
dc.identifier.issn1932-6203-
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/23504-
dc.description.abstractBackground: Viral hepatitis B, C and delta still remain a serious problem worldwide. In Colombia, data from 1980s described that HBV and HDV infection are important causes of hepatitis, but little is known about HCV infection. The aim of this study was to determine the currently frequency of HBV, HCV and HDV in four different Colombian regions. Methodology/Principal Findings: This study was conducted in 697 habitants from 4 Colombian departments: Amazonas, Choco, Magdalena and San Andres Islands. Epidemiological data were obtained from an interview applied to each individual aiming to evaluate risk factors related to HBV, HCV or HDV infections. All samples were tested for HBsAg, anti-HBc, anti-HBs and anti-HCV markers. Samples that were positive to HBsAg and/or anti-HBc were tested to anti-HDV. Concerning the geographical origin of the samples, the three HBV markers showed a statistically significant difference: HBsAg (p = 0.033) and anti-HBc (p < 0.001) were more frequent in Amazonas and Magdalena departments. Isolated anti-HBs (a marker of previous vaccination) frequencies were: Choco (53.26%), Amazonas (32.88%), Magdalena (17.0%) and San Andres (15.33%) p < 0.001. Prevalence of anti-HBc increased with age; HBsAg varied from 1.97 to 8.39% (p = 0.033). Amazonas department showed the highest frequency for anti-HCV marker (5.68%), while the lowest frequency was found in San Andres Island (0.66%). Anti-HDV was found in 9 (5.20%) out of 173 anti-HBc and/or HBsAg positive samples, 8 of them from the Amazonas region and 1 from them Magdalena department. Conclusions/Significance: In conclusion, HBV, HCV and HDV infections are detected throughout Colombia in frequency levels that would place some areas as hyperendemic for HBV, especially those found in Amazonas and Magdalena departments. Novel strategies to increase HBV immunization in the rural population and to strengthen HCV surveillance are reinforced by these results.-
dc.description.sponsorshipFundacao de Amparo a Pesquisa do Estado de Sao Paulo - FAPESP [2007/53457-7, 2008/50461-6]-
dc.description.sponsorshipCNPq-
dc.description.sponsorshipSao Paulo, SP, Brazil-
dc.description.sponsorshipPontificia Universidad Javeriana, Bogota, Colombia-
dc.language.isoeng-
dc.publisherPUBLIC LIBRARY SCIENCE-
dc.relation.ispartofPlos One-
dc.rightsopenAccess-
dc.subject.otherlatin-america-
dc.subject.othersouth-america-
dc.subject.othermolecular characterization-
dc.subject.othersanta-marta-
dc.subject.othergenotype-i-
dc.subject.otherinfection-
dc.subject.otherdisease-
dc.subject.othervenezuela-
dc.subject.othersequence-
dc.subject.otherindians-
dc.titleHepatitis B (HBV), Hepatitis C (HCV) and Hepatitis Delta (HDV) Viruses in the Colombian Population-How Is the Epidemiological Situation?-
dc.typearticle-
dc.rights.holderCopyright PUBLIC LIBRARY SCIENCE-
dc.identifier.doi10.1371/journal.pone.0018888-
dc.identifier.pmid21559488-
dc.subject.wosMultidisciplinary Sciences-
dc.type.categoryoriginal article-
dc.type.versionpublishedVersion-
hcfmusp.author.externalFERNANDEZ, Maria Fernanda Gutierrez:Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil; Pontificia Javeriana Univ, Dept Microbiol, Virol Lab, Bogota, Colombia-
hcfmusp.description.articlenumbere18888-
hcfmusp.description.issue4-
hcfmusp.description.volume6-
hcfmusp.origemWOS-
hcfmusp.origem.id2-s2.0-79955758226-
hcfmusp.origem.idWOS:000290024700033-
hcfmusp.publisher.citySAN FRANCISCO-
hcfmusp.publisher.countryUSA-
hcfmusp.relation.referenceMora MVA, 2011, INFECT GENET EVOL, V11, P103, DOI 10.1016/j.meegid.2010.10.003-
hcfmusp.relation.referenceSchmunis GA, 2005, CLIN MICROBIOL REV, V18, P12, DOI 10.1128/CMR.18.1.12-29.2005-
hcfmusp.relation.referenceRadjef N, 2004, J VIROL, V78, P2537, DOI 10.1128/JVI.78.5.2537-2544.2004-
hcfmusp.relation.referenceGomes-Gouvea MS, 2009, J GEN VIROL, V90, P2638, DOI 10.1099/vir.0.013615-0-
hcfmusp.relation.referenceLAI MMC, 1995, ANNU REV BIOCHEM, V64, P259-
hcfmusp.relation.referenceQuintero A, 2001, J MED VIROL, V64, P356, DOI 10.1002/jmv.1058-
hcfmusp.relation.referenceShepard CW, 2005, LANCET INFECT DIS, V5, P558, DOI 10.1016/S1473-3099(05)70216-4-
hcfmusp.relation.referenceHADLER SC, 1984, ANN INTERN MED, V100, P339-
hcfmusp.relation.referenceBostan N, 2010, CRIT REV MICROBIOL, V36, P91, DOI 10.3109/10408410903357455-
hcfmusp.relation.referencePasquier C, 2005, J MED VIROL, V77, P390, DOI 10.1002/jmv.20468-
hcfmusp.relation.referenceWANG KS, 1986, NATURE, V323, P508, DOI 10.1038/323508a0-
hcfmusp.relation.referenceLe Gal F, 2006, EMERG INFECT DIS, V12, P1447-
hcfmusp.relation.referenceBUITRAGO B, 1986, HEPATOLOGY, V6, P1292, DOI 10.1002/hep.1840060611-
hcfmusp.relation.referenceGaeta GB, 2000, HEPATOLOGY, V32, P824, DOI 10.1053/jhep.2000.17711-
hcfmusp.relation.referenceMAKINO S, 1987, NATURE, V329, P343, DOI 10.1038/329343a0-
hcfmusp.relation.referenceLavanchy D, 2004, J VIRAL HEPATITIS, V11, P97, DOI 10.1046/j.1365-2893.2003.00487.x-
hcfmusp.relation.referenceWu JC, 1998, J GEN VIROL, V79, P1105-
hcfmusp.relation.referenceLJUNGGREN KE, 1985, HEPATOLOGY, V5, P299, DOI 10.1002/hep.1840050225-
hcfmusp.relation.referenceCASEY JL, 1993, P NATL ACAD SCI USA, V90, P9016, DOI 10.1073/pnas.90.19.9016-
hcfmusp.relation.referenceBensabath G, 1987, Bull Pan Am Health Organ, V21, P16-
hcfmusp.relation.referenceBUITRAGO B, 1991, BIOMEDICA, V11, P5-
hcfmusp.relation.referenceCarrilho FJ, 1998, THERAPIES FOR VIRAL HEPATITIS, P25-
hcfmusp.relation.referenceShakil AO, 1997, VIROLOGY, V234, P160, DOI 10.1006/viro.1997.8644-
hcfmusp.relation.referenceCHAO YC, 1990, VIROLOGY, V178, P384-
hcfmusp.relation.referencede la Hoz F, 1992, BIOMEDICA, V12, P5-
hcfmusp.relation.referenceEchevarría José M, 2003, Cad Saude Publica, V19, P1583, DOI 10.1590/S0102-311X2003000600003-
hcfmusp.relation.referenceEspinal C, 1998, BIOMEDICA, V18, P216-
hcfmusp.relation.referenceFAY OH, 1990, VACCINE, V8, pS100-
hcfmusp.relation.referenceGAYOTTO LCD, 1991, PROG CLIN BIOL RES, V364, P123-
hcfmusp.relation.referenceGish RG, 2006, J VIRAL HEPATITIS, V13, P787, DOI 10.1111/j.1365-2893.2006.00787.x-
hcfmusp.relation.referenceBeltrân Mauricio, 2005, J Clin Virol, V34 Suppl 2, pS33, DOI 10.1016/S1386-6532(05)80032-0-
hcfmusp.relation.referenceMARTINEZ M, 1991, BIOMEDICA, V11, P20-
hcfmusp.relation.reference*MIN SAL, 2002, B EP SEM SIT HEP B C-
hcfmusp.relation.reference*MIN SAL, 1996, MAN NORM TECN ADM PR, pCH11-
hcfmusp.relation.referenceMora MVA, 2010, J GEN VIROL, V91, P501, DOI 10.1099/vir.0.015958-0-
hcfmusp.relation.referenceMora MVA, 2010, J MED VIROL, V82, P1889, DOI 10.1002/jmv.21908-
hcfmusp.relation.referencePrieto F, 2003, BIOMEDICA, V8, P2-
hcfmusp.relation.referenceRAMSEY GH, 1931, FEVER JAUNDICE PROVI-
hcfmusp.relation.referenceREEVES WC, 1975, AM J TROP MED HYG, V24, P873-
hcfmusp.relation.referenceSakugawa H, 1999, J MED VIROL, V58, P366, DOI 10.1002/(SICI)1096-9071(199908)58:4<366::AID-JMV8>3.0.CO;2-X-
hcfmusp.relation.referenceSchmunis GA, 1998, EMERG INFECT DIS, V4, P5-
hcfmusp.relation.referenceSlusarczyk J, 2000, VACCINE, V18, pS4, DOI 10.1016/S0264-410X(99)00451-X-
hcfmusp.relation.referenceSoza Alejandro, 2010, Ann Hepatol, V9 Suppl, P33-
hcfmusp.relation.referenceTanaka J, 2000, VACCINE, V18, pS17, DOI 10.1016/S0264-410X(99)00455-7-
hcfmusp.relation.referenceTe Helen S, 2010, Clin Liver Dis, V14, P1, DOI 10.1016/j.cld.2009.11.009-
hcfmusp.relation.referenceTe HS, 2010, CLIN LIVER DIS, V14, pvii, DOI 10.1016/J.CLD.2009.11.009]-
hcfmusp.relation.referenceTorres JR, 1996, GUT, V38, pS48, DOI 10.1136/gut.38.Suppl_2.S48-
hcfmusp.relation.referenceWatanabe H, 2003, J GEN VIROL, V84, P3275, DOI 10.1099/vir.0.19499-0-
hcfmusp.relation.reference*WHO, 2001, HEP DELT, P18-
hcfmusp.relation.referenceYu H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009297-
dc.description.indexMEDLINE-
hcfmusp.citation.scopus37-
hcfmusp.scopus.lastupdate2022-06-17-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MGT
Departamento de Gastroenterologia - FM/MGT

Artigos e Materiais de Revistas Científicas - FM/MPT
Departamento de Patologia - FM/MPT

Artigos e Materiais de Revistas Científicas - HC/ICHC
Instituto Central - HC/ICHC

Artigos e Materiais de Revistas Científicas - LIM/01
LIM/01 - Laboratório de Informática Médica

Artigos e Materiais de Revistas Científicas - LIM/07
LIM/07 - Laboratório de Gastroenterologia Clínica e Experimental


Files in This Item:
File Description SizeFormat 
art_ALVARADO-MORA_Hepatitis_B_HBV_Hepatitis_C_HCV_and_Hepatitis_2011.PDFpublishedVersion (English)153.91 kBAdobe PDFThumbnail
View/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.